Patients are returning in Europe, but China and US lag behind, says Coloplast's CEO
Things are looking better in Europe for Medtech firm Coloplast, as patient numbers are returning to pre-Covid-19 levels. However, challenges remain outside the region, CEO Kristian Villumsen says.
by marketwire, translated by daniel pedersen
Signs of a patient influx recovery for Coloplast’s segment have appeared – particularly in Europe, where the patient numbers are almost the same as prior to the Covid-10 pandemic, says the medtech company’s CEO, Kristian Villumsen, in an interview with MarketWire.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish bank changes Coloplast recommendation to "buy"
For subscribers
Coloplast upgrades growth expectations following acquisition
For subscribers
